NCT04689048 2026-04-22
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
Baptist Health South Florida
Phase 1 Recruiting
Clinical Trials
970 trialsNCT05030298 2026-04-22
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
Mayo Clinic
Phase 1 Recruiting
NCT05101551 2026-04-22
PARPAML
Stanford University
Phase 1 Recruiting
NCT05334004 2026-04-22
Lopinavir/Ritonavir in PLWH With High-Grade AIN
University of Wisconsin, Madison
Phase 1 Recruiting
NCT05366179 2026-04-22
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT05562791 2026-04-22
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06347068 2026-04-22
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT06949410 2026-04-22
HER2 Vaccine for Locally Advanced Breast Cancer
Indiana University
Phase 1 Recruiting
NCT07320235 2026-04-22
IMAGINE
Icahn School of Medicine at Mount Sinai
Phase 1 Recruiting
NCT07401277 2026-04-22
Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum
West Virginia University
Phase 1 Recruiting
NCT02600949 2026-04-21
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05917145 2026-04-21
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma
Mayo Clinic
Phase 1 Recruiting
NCT06430541 2026-04-21
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
University of Colorado, Denver
Phase 1 Recruiting
NCT06622005 2026-04-21
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT06964009 2026-04-21
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT07137494 2026-04-21
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07541573 2026-04-21
Phase 1a/1b GTB-5550 in Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Recruiting
NCT06859008 2026-04-20
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Recruiting
NCT07025538 2026-04-20
Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
City of Hope Medical Center
Phase 1 Recruiting
NCT07219147 2026-04-20
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT07538648 2026-04-20
A Phase II Clinical Study Evaluating the Effectiveness of Injectable NC527-X in Intraoperative Imaging for Patients With Solid Tumors
Zhejiang Cancer Hospital
Phase 1 Recruiting
NCT02390635 2026-04-17
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04158635 2026-04-17
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT05698524 2026-04-17
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
Phase 1 Recruiting
NCT06833866 2026-04-17
Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 1 Recruiting
NCT07218913 2026-04-17
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
City of Hope Medical Center
Phase 1 Recruiting
NCT07537010 2026-04-17
3D1015 Injection for Patients With mCRPC
Affiliated Hospital of Jiangnan University
Phase 1 Recruiting
NCT03922555 2026-04-16
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
Massachusetts General Hospital
Phase 1 Recruiting
NCT04615013 2026-04-16
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05101213 2026-04-16
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05335811 2026-04-16
First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06066424 2026-04-16
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06083883 2026-04-16
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06545682 2026-04-16
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06576037 2026-04-16
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06660420 2026-04-16
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07101432 2026-04-16
Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07532902 2026-04-16
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT03114462 2026-04-15
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03604315 2026-04-15
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03710421 2026-04-15
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
City of Hope Medical Center
Phase 1 Recruiting
NCT04308330 2026-04-15
NYMC195
New York Medical College
Phase 1 Recruiting
NCT04897321 2026-04-15
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT04972942 2026-04-15
ALLO-T-DART
New York Medical College
Phase 1 Recruiting
NCT05039801 2026-04-15
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05394259 2026-04-15
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06126744 2026-04-15
PuMP
Duke University
Phase 1 Recruiting
NCT06666712 2026-04-15
TPT CED rHGG
Columbia University
Phase 1 Recruiting
NCT07025564 2026-04-15
MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Recruiting
NCT07166419 2026-04-15
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting